市場調査レポート

商品コード

1771611

ワクチンの市場規模、シェア、動向分析レポート：タイプ別、投与経路別、適応疾患別、年齢層別、流通チャネル別、地域別、セグメント予測、2025年～2033年

Vaccine Market Size, Share & Trends Analysis Report By Type (Subunit, mRNA), By Route Of Administration (Oral), By Disease Indication (HPV, MMR), By Age Group (Adult), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

出版日: 2025年06月17日
発行: Grand View Research
ページ情報: 英文 180 Pages
納期: 2～10営業日

カスタマイズ可能

価格

Unprintable PDF & Excel (Single User License)

USD 5,950 877,506円

レポートPDF及びExcelを1名様のみがご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷はできません。

Printable PDF & Excel (5-User License)

USD 6,950 1,024,986円

レポートPDF及びExcelを同一企業内の同一部署における5名様までの方にご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷は可能です。

Printable PDF & Excel (Enterprise License)

USD 8,950 1,319,946円

レポートの購入企業、およびその子会社、関連会社の方にご使用頂けるライセンスです。PDF及びExcelのテキスト等のコピー＆ペースト、印刷は可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=147.48円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

ワクチン市場の成長と動向：

Grand View Research社の最新レポートによると、世界のワクチン市場規模は2033年までに1,519億6,000万米ドルに達する見込みです。

同市場は2025年から2033年にかけてCAGR 7.8%で拡大すると予測されています。この成長の背景には、予防接種プログラムの増加や、RSVやクラミジアなどの疾患に対するワクチンの開発があります。公衆衛生上懸念される疾患に対するワクチンへのアクセス改善は大きく進展しています。多くの新しいワクチンが開発され、世界的に配布されるようになり、その結果、数え切れないほどの人命が救われ、さまざまな疾病が予防されるようになりました。

さらに、ワクチン市場には、ワクチンへのアクセスを改善し、新しいワクチンを開発し、ワクチンの安全性を確保することを目的としたイニシアチブがいくつか存在します。これらのイニシアチブには、国際機関、政府、民間企業、慈善団体が関与しています。協調と革新を通じて、これらのイニシアチブは世界の健康課題に対処し、公衆衛生の成果を向上させるのに役立っています。例えば、COVAXはCOVIDワクチンへの公平なアクセスを確保することを目的とした世界的イニシアティブです。このイニシアチブは、Gavi、ワクチンアライアンス、世界保健機関（WHO）、疫病対策イノベーション連合（CEPI）が共同で主導しています。

2021年に世界保健機関（WHO）加盟国にワクチンを供給するワクチン製造業者は90社以上あるが、供給は依然として、多様な展開可能技術と世界のリーチを持つ10社未満の製造業者に大きく依存しています。このような集中は、特にアフリカと東地中海地域において、地域的な供給不安と市場の健康問題につながっています。米国では、2023年後半にCOVIDワクチン市場が民営化される可能性があると予想されています。この民営化により、COVIDワクチンの価格が上昇し、他のプレーヤーにも市場が開放される可能性があります。例えば、ModernaとPfizer BioNTechの両社は、それぞれのmRNA COVIDワクチンの価格を1回あたり110～130米ドル程度に引き上げる可能性があると発表しています。

ワクチン市場のハイライト

2024年のワクチン市場はサブユニットワクチンが44.30%のシェアを占め、予測期間中に急成長が見込まれます。
ワクチンの投与には非経口投与が好まれるため、このセグメントは2024年に96.65%のシェアでワクチン市場を独占します。
ウイルス性疾患分野は2023年に63.79%のシェアでワクチン市場を独占し、その主因はCOVID-19ワクチンです。
2024年のワクチン市場では、成人が55.73%のシェアを占めました。COVID-19用を含む成人用ワクチン接種が世界の数量ベースで75%を占め、小児用ワクチンは約20%でした。
2024年のワクチン市場は、政府系サプライヤーが54.81%のシェアを占めました。
北米ワクチン市場は予測期間中最も速いCAGRで成長すると予測されます。

市場セグメンテーションと範囲
市場系統の見通し
- 親市場の見通し
- 関連/補助市場展望
市場動向と展望
市場力学
- 世界中で予防接種の重要性が高まっている
- 慢性疾患と感染症の負担増大
- ワクチン開発における技術の進歩
市場抑制要因分析
- ヘルスケアインフラの不足
- 予防接種の費用
ビジネス環境分析
- SWOT分析：要因別（政治・法律、経済・技術）
- ポーターのファイブフォース分析
COVID-19の影響分析

第3章タイプのビジネス分析

タイプの市場シェア、2024年と2033年
セグメントダッシュボード
ワクチン市場：タイプ別展望
2021年から2033年までの市場規模と予測および動向分析
サブユニットワクチン
- サブユニットワクチン市場、2021年～2033年
- 組み換えワクチン
- 結合ワクチン
- トキソイドワクチン
不活性化
生弱毒化
mRNAワクチン
ウイルスベクターワクチン

第4章投与経路のビジネス分析

投与経路の市場シェア、2024年と2033年
セグメントダッシュボード
ワクチン市場：投与経路別展望
2021年から2033年までの市場規模と予測および動向分析
経口
非経口
鼻腔

第5章適応疾患のビジネス分析

適応疾患の市場シェア、2024年および2033年
セグメントダッシュボード
ワクチン市場：適応疾患別展望
2021年から2033年までの市場規模と予測および動向分析
ウイルス性疾患
- ウイルス性疾患ワクチン市場、2021年～2033年
- 肝炎
- インフルエンザ
- HPV
- MMR
- ロタウイルス
- 帯状疱疹
- COVID-19
- その他
細菌ワクチン
- 細菌ワクチン市場、2021年～2033年
- 髄膜炎菌感染症
- 肺炎球菌感染症
- 二回経口投与
- その他
がんワクチン
アレルギーワクチン

第6章年齢層のビジネス分析

年齢層の市場シェア、2024年および2033年
セグメントダッシュボード
ワクチン市場：年齢層別展望
2021年から2033年までの市場規模と予測および動向分析
小児
成人

第7章流通チャネルのビジネス分析

流通チャネルの市場シェア、2024年および2033年
セグメントダッシュボード
ワクチン市場：流通チャネル別展望
2021年から2033年までの市場規模と予測および動向分析
病院および薬局
政府サプライヤー
その他

第8章地域のビジネス分析

地域別ワクチン市場シェア、2024年および2033年
北米
- 北米のワクチン市場2021年～2033年
- 米国
- カナダ
- メキシコ
欧州
- 欧州のワクチン市場2021年～2033年
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- デンマーク
- スウェーデン
- ノルウェー
アジア太平洋
- アジア太平洋地域のワクチン市場、2021年～2033年
- 日本
- 中国
- インド
- 韓国
- オーストラリア
- タイ
ラテンアメリカ
- ラテンアメリカのワクチン市場、2021年～2033年
- ブラジル
- アルゼンチン
中東・アフリカ
- 中東・アフリカのワクチン市場、2021年から2033年
- 南アフリカ
- サウジアラビア
- アラブ首長国連邦
- クウェート

第9章競合情勢

参入企業の概要
財務実績
参入企業
- マーケットリーダー
- ワクチン市場シェア分析、2023年
- 企業プロファイル
- 戦略マッピング
  - Serum Institute of India Pvt. Ltd.
  - Seqirus
  - Sanofi
  - GSK Plc.
  - Merck & Co., Inc.
  - Pfizer Inc.
  - Moderna Inc.
  - Sinovac
  - BioNTech SE
  - AstraZeneca

図表

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Vaccine Market, by Region, 2021 - 2033 (USD Billion)
Table 4 Global Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 5 Global Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 6 Global Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 7 Global Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 8 Global Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 9 North America Vaccine Market, by Country, 2021 - 2033 (USD Billion)
Table 10 North America Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 11 North America Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 12 North America Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 13 North America Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 14 North America Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 15 U.S. Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 16 U.S. Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 17 U.S. Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 18 U.S. Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 19 U.S. Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 20 Canada Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 21 Canada Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 22 Canada Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 23 Canada Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 24 Canada Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 25 Mexico Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 26 Mexico Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 27 Mexico Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 28 Mexico Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 29 Mexico Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 30 Europe Vaccine Market, by Country, 2021 - 2033 (USD Billion)
Table 31 Europe Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 32 Europe Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 33 Europe Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 34 Europe Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 35 Europe Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 36 Germany Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 37 Germany Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 38 Germany Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 39 Germany Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 40 Germany Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 41 UK Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 42 UK Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 43 UK Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 44 UK Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 45 UK Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 46 France Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 47 France Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 48 France Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 49 France Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 50 France Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 51 Italy Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 52 Italy Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 53 Italy Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 54 Italy Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 55 Italy Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 56 Spain Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 57 Spain Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 58 Spain Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 59 Spain Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 60 Spain Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 61 Denmark Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 62 Denmark Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 63 Denmark Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 64 Denmark Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 65 Denmark Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 66 Sweden Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 67 Sweden Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 68 Sweden Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 69 Sweden Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 70 Sweden Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 71 Norway Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 72 Norway Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 73 Norway Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 74 Norway Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 75 Norway Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 76 Asia Pacific Vaccine Market, by Country, 2021 - 2033 (USD Billion)
Table 77 Asia Pacific Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 78 Asia Pacific Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 79 Asia Pacific Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 80 Asia Pacific Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 81 Asia Pacific Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 82 China Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 83 China Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 84 China Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 85 China Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 86 China Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 87 Japan Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 88 Japan Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 89 Japan Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 90 Japan Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 91 Japan Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 92 India Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 93 India Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 94 India Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 95 India Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 96 India Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 97 South Korea Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 98 South Korea Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 99 South Korea Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 100 South Korea Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 101 South Korea Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 102 Australia Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 103 Australia Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 104 Australia Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 105 Australia Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 106 Australia Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 107 Thailand Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 108 Thailand Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 109 Thailand Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 110 Thailand Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 111 Thailand Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 112 Latin America Vaccine Market, by Country, 2021 - 2033 (USD Billion)
Table 113 Latin America Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 114 Latin America Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 115 Latin America Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 116 Latin America Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 117 Latin America Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 118 Brazil Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 119 Brazil Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 120 Brazil Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 121 Brazil Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 122 Brazil Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 123 Argentina Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 124 Argentina Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 125 Argentina Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 126 Argentina Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 127 Argentina Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 128 Middle East & Africa Vaccine Market, by Country, 2021 - 2033 (USD Billion)
Table 129 Middle East & Africa Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 130 Middle East & Africa Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 131 Middle East & Africa Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 132 Middle East & Africa Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 133 Middle East & Africa Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 134 South Africa Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 135 South Africa Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 136 South Africa Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 137 South Africa Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 138 South Africa Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 139 Saudi Arabia Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 140 Saudi Arabia Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 141 Saudi Arabia Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 142 Saudi Arabia Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 143 Saudi Arabia Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 144 UAE Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 145 UAE Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 146 UAE Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 147 UAE Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 148 UAE Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 149 Kuwait Vaccine Market, by Type, 2021 - 2033 (USD Billion)
Table 150 Kuwait Vaccine Market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 151 Kuwait Vaccine Market, by Disease Indication, 2021 - 2033 (USD Billion)
Table 152 Kuwait Vaccine Market, by Age Group, 2021 - 2033 (USD Billion)
Table 153 Kuwait Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Billion)
Table 154 Financial performance
Table 155 Key companies undergoing expansions
Table 156 Key companies undergoing acquisitions
Table 157 Key companies undergoing collaborations
Table 158 Key companies launching new products/services
Table 159 Key companies undergoing partnerships
Table 160 Key companies undertaking other strategies

List of Figures

Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 Vaccine Market Segmentation
Fig. 7 Market Snapshot, 2024
Fig. 8 Market Trends & Outlook
Fig. 9 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 10 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 11 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter's Five Forces Analysis
Fig. 14 Market Penetration Vs Growth Prospect Mapping, 2023
Fig. 15 Global Vaccine Market: By Type, Movement Analysis
Fig. 16 Global Vaccine Market, for Subunit Vaccines, 2021 - 2033 (USD Billion)
Fig. 17 Global Vaccine Market, for Recombinant vaccines, 2021 - 2033 (USD Billion)
Fig. 18 Global Vaccine Market, for Conjugate Vaccines, 2021 - 2033 (USD Billion)
Fig. 19 Global Vaccine Market, for Toxoid vaccines, 2021 - 2033 (USD Billion)
Fig. 20 Global Vaccine Market, for Inactivated, 2021 - 2033 (USD Billion)
Fig. 21 Global Vaccine Market, for Live Attenuated2021 - 2033 (USD Billion)
Fig. 22 Global Vaccine Market, for mRNA vaccines, 2021 - 2033 (USD Billion)
Fig. 23 Global Vaccine Market, for Viral vector vaccines, 2021 - 2033 (USD Billion)
Fig. 24 Global Vaccine Market: By Route of Administration, Movement Analysis
Fig. 25 Global Vaccine Market, for Oral, 2021 - 2033 (USD Billion)
Fig. 26 Global Vaccine Market, for Parenteral, 2021 - 2033 (USD Billion)
Fig. 27 Global Vaccine Market, for Nasal2021 - 2033 (USD Billion)
Fig. 28 Global Vaccine Market: Disease Indication, Movement Analysis
Fig. 29 Global Vaccine Market, for Viral Diseases, 2021 - 2033 (USD Billion)
Fig. 30 Global Vaccine Market, for Hepatitis, 2021 - 2033 (USD Billion)
Fig. 31 Global Vaccine Market, for Influenza2021 - 2033 (USD Billion)
Fig. 32 Global Vaccine Market, for HPV, 2021 - 2033 (USD Billion)
Fig. 33 Global Vaccine Market, for MMR, 2021 - 2033 (USD Billion)
Fig. 34 Global Vaccine Market, for Rotavirus, 2021 - 2033 (USD Billion)
Fig. 35 Global Vaccine Market, for Herpes Zoster, 2021 - 2033 (USD Billion)
Fig. 36 Global Vaccine Market, for COVID-19, 2021 - 2033 (USD Billion)
Fig. 37 Global Vaccine Market, for Bacterial Vaccines, 2021 - 2033 (USD Billion)
Fig. 38 Global Vaccine Market, for Meningococcal Diseases, 2021 - 2033 (USD Billion)
Fig. 39 Global Vaccine Market, for Pneumococcal diseases, 2021 - 2033 (USD Billion)
Fig. 40 Global Vaccine Market, for DPT, 2021 - 2033 (USD Billion)
Fig. 41 Global Vaccine Market, for Others, 2021 - 2033 (USD Billion)
Fig. 42 Global Vaccine Market, for Cancer Vaccines, 2021 - 2033 (USD Billion)
Fig. 43 Global Vaccine Market, for Allergy Vaccines, 2021 - 2033 (USD Billion)
Fig. 44 Global Vaccine Market: Age Group, Movement Analysis
Fig. 45 Global Vaccine Market, for Pediatric,2021 - 2033 (USD Billion)
Fig. 46 Global Vaccine Market, for Adult ,2021 - 2033 (USD Billion)
Fig. 47 Global Vaccine Market: Distribution Channel, Movement Analysis
Fig. 48 Global Vaccine Market, for Hospital & Retail Pharmacies,2021 - 2033 (USD Billion)
Fig. 49 Global Vaccine Market, for Government Suppliers,2021 - 2033 (USD Billion)
Fig. 50 Global Vaccine Market, for Others2021 - 2033 (USD Billion)
Fig. 51 Regional Marketplace: Key Takeaways Vaccine Market,
Fig. 52 Regional Outlook, 2024 & 2033 Vaccine Market,
Fig. 53 Global Vaccine Market: Region Movement Analysis
Fig. 54 North America Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 55 U.S. Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 56 Canada Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 57 Europe Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 58 Germany Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 59 UK Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 60 France Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 61 Italy Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 62 Spain Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 63 Denmark Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 64 Sweden Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 65 Norway Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 66 Asia Pacific Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 67 Japan Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 68 China Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 69 India Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 70 Australia Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 71 South Korea Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 72 Thailand Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 73 Latin America Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 74 Brazil Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 75 Mexico Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 76 Argentina Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 77 Middle East and Africa Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 78 South Africa Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 79 Saudi Arabia Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 80 UAE Vaccine Market, 2021 - 2033 (USD Billion)
Fig. 81 Kuwait Vaccine Market, 2021 - 2033 (USD Billion)

Product Code: 978-1-68038-990-6

Vaccine Market Growth & Trends:

The global vaccine market size is expected to reach USD 151.96 billion by 2033, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.8% from 2025 to 2033. The growth is attributed to the rising immunization programmes, and the development of vaccines for diseases, such as RSV and Chlamydia amongst others. There has been significant progress in improving access to vaccines for diseases of public health concern. Many new vaccines have been developed and distributed globally, resulting in the saving of countless lives and the prevention of various illnesses.

Furthermore, there are several initiatives in the vaccine market aimed at improving access to vaccines, developing new vaccines, and ensuring vaccine safety. These initiatives involve international organizations, governments, private sector entities, and philanthropic organizations. Through collaboration and innovation, these initiatives are helping to address global health challenges and improve public health outcomes. For instance, COVAX is a global initiative aimed at ensuring equitable access to COVID vaccines. The initiative is co-led by Gavi, the Vaccine Alliance, the World Health Organization (WHO), and the Coalition for Epidemic Preparedness Innovations (CEPI).

Although there are over 90 vaccine manufacturers supplying vaccines to World Health Organization Member States in 2021, supply remains highly dependent on fewer than 10 manufacturers with diverse deployable technology and global reach. This concentration leads to regional supply insecurity and market health issues, particularly in the African and Eastern Mediterranean regions. It is anticipated that the COVID vaccine market could go private in the second half of 2023 in the U.S. This privatization may lead to an increase in prices of COVID vaccines and open up the market for other players as well. For instance, both Moderna and Pfizer BioNTech have announced that the prices of their respective mRNA COVID vaccines could increase to around USD 110 to USD 130 per shot.

Vaccine Market Report Highlights:

The subunit Vaccines segment dominated the vaccine market with a share of 44.30% in 2024 and is expected to experience rapid growth during the forecast period.
Parenteral administration is highly preferred for administering vaccines and hence the segment dominated the vaccine market with a share of 96.65% in 2024.
The viral diseases segment dominated the vaccine market with a share of 63.79% in 2023, majorly attributed to COVID-19 vaccines.
Adult accounted for a share of 55.73% in the vaccine market in 2024. Adult vaccination, including those for COVID-19, comprised 75% in terms of volume globally, while pediatric vaccines accounted for about 20%.
Government suppliers dominated the vaccine market in 2024 with a share of 54.81%.
North America vaccines market is estimated to grow at the fastest CAGR over the forecast period.

Chapter 1. Methodology And Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Route of Administration
- 1.2.3. Disease Indication
- 1.2.4. Age Group
- 1.2.5. Distribution Channel
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
  - 1.4.5.1. Data for primary interviews in North America
  - 1.4.5.2. Data for primary interviews in Europe
  - 1.4.5.3. Data for primary interviews in Asia Pacific
  - 1.4.5.4. Data for primary interviews in Latin America
  - 1.4.5.5. Data for primary interviews in MEA
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Market Variables, Trends, & Scope

2.1. Market Segmentation and Scope
2.2. Market Lineage Outlook
- 2.2.1. Parent Market Outlook
- 2.2.2. Related/Ancillary Market Outlook
2.3. Market Trends and Outlook
2.4. Market Dynamics
- 2.4.1. Rise in the importance of immunization across the globe
- 2.4.2. Growing Burden of Chronic and Infectious Diseases
- 2.4.3. Technology advancements in the vaccination development
2.5. Market Restraint Analysis
- 2.5.1. Lack of healthcare infrastructure
- 2.5.2. Cost of immunization
2.6. Business Environment Analysis
- 2.6.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
- 2.6.2. Porter's Five Forces Analysis
2.7. COVID-19 Impact Analysis

Chapter 3. Type Business Analysis

3.1. Type Market Share, 2024 & 2033
3.2. Segment Dashboard
3.3. Vaccines Market by Type Outlook
3.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
3.5. Subunit Vaccines
- 3.5.1. Vaccine Market for Subunit Vaccines, 2021 - 2033 (USD Billion)
- 3.5.2. Recombinant vaccines
  - 3.5.2.1. Vaccine Market for Recombinant vaccines, 2021 - 2033 (USD Billion)
- 3.5.3. Conjugate Vaccines
  - 3.5.3.1. Vaccine Market for Conjugate vaccines, 2021 - 2033 (USD Billion)
- 3.5.4. Toxoid vaccines
  - 3.5.4.1. Vaccine Market for Toxoid vaccines, 2021 - 2033 (USD Billion)
3.6. Inactivated
- 3.6.1. Vaccine Market for Inactivated, 2021 - 2033 (USD Billion)
3.7. Live Attenuated
- 3.7.1. Vaccine Market for Live Attenuated, 2021 - 2033 (USD Billion)
3.8. mRNA vaccines
- 3.8.1. Vaccine Market for mRNA vaccines, 2021 - 2033 (USD Billion)
3.9. Viral vector vaccines
- 3.9.1. Vaccine Market for Viral vector vaccines, 2021 - 2033 (USD Billion)

Chapter 4. Route Of Administration Business Analysis

4.1. Route of administration Market Share, 2024 & 2033
4.2. Segment Dashboard
4.3. Vaccines Market by Route of administration Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
4.5. Oral
- 4.5.1. Vaccine Market for Oral, 2021 - 2033 (USD Billion)
4.6. Parenteral
- 4.6.1. Vaccine Market for Parenteral, 2021 - 2033 (USD Billion)
4.7. Nasal
- 4.7.1. Vaccine Market for Nasal, 2021 - 2033 (USD Billion)

Chapter 5. Disease Indication Business Analysis

5.1. Disease Indication Market Share, 2024 & 2033
5.2. Segment Dashboard
5.3. Vaccines Market by Disease Indication Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.5. Viral Diseases
- 5.5.1. Vaccine Market for Viral Diseases, 2021 - 2033 (USD Billion)
- 5.5.2. Hepatitis
  - 5.5.2.1. Vaccine Market for Hepatitis, 2021 - 2033 (USD Billion)
- 5.5.3. Influenza
  - 5.5.3.1. Vaccine Market for Influenza, 2021 - 2033 (USD Billion)
- 5.5.4. HPV
  - 5.5.4.1. Vaccine Market for HPV, 2021 - 2033 (USD Billion)
- 5.5.5. MMR
  - 5.5.5.1. Vaccine Market for MMR, 2021 - 2033 (USD Billion)
- 5.5.6. Rotavirus
  - 5.5.6.1. Vaccine Market for Rotavirus, 2021 - 2033 (USD Billion)
- 5.5.7. Herpes Zoster
  - 5.5.7.1. Vaccine Market for Herpes Zoster, 2021 - 2033 (USD Billion)
- 5.5.8. COVID-19
  - 5.5.8.1. Vaccine Market for Covid-19, 2021 - 2033 (USD Billion)
- 5.5.9. Others
  - 5.5.9.1. Vaccine Market for Others, 2021 - 2033 (USD Billion)
5.6. Bacterial Vaccines
- 5.6.1. Vaccine Market for Bacterial Vaccines, 2021 - 2033 (USD Billion)
- 5.6.2. Meningococcal Diseases
  - 5.6.2.1. Vaccine Market for Meningococcal Diseases, 2021 - 2033 (USD Billion)
- 5.6.3. Pneumococcal Diseases
  - 5.6.3.1. Vaccine Market for Pneumococcal Diseases, 2021 - 2033 (USD Billion)
- 5.6.4. DPT
  - 5.6.4.1. Vaccine Market for DPT, 2021 - 2033 (USD Billion)
- 5.6.5. Others
  - 5.6.5.1. Vaccine Market for Others, 2021 - 2033 (USD Billion)
5.7. Cancer Vaccines
- 5.7.1. Vaccine Market for Cancer Vaccines, 2021 - 2033 (USD Billion)
5.8. Allergy Vaccines
- 5.8.1. Vaccine Market for Allergy Vaccines, 2021 - 2033 (USD Billion)

Chapter 6. Age Group Business Analysis

6.1. Age Group Market Share, 2024 & 2033
6.2. Segment Dashboard
6.3. Vaccines Market by Age Group Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.5. Pediatric
- 6.5.1. Vaccine Market for Pediatric, 2021 - 2033 (USD Billion)
6.6. Adult
- 6.6.1. Vaccine Market for Adult, 2021 - 2033 (USD Billion)

Chapter 7. Distribution Channel Business Analysis

7.1. Distribution Channel Market Share, 2024 & 2033
7.2. Segment Dashboard
7.3. Vaccines Market by Distribution Channel Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
7.5. Hospital & Retail Pharmacies
- 7.5.1. Vaccine Market for Hospital & Retail Pharmacies, 2021 - 2033 (USD Billion)
7.6. Government Suppliers
- 7.6.1. Vaccine Market for Government Suppliers 2021 - 2033 (USD Billion)
7.7. Others
- 7.7.1. Vaccine Market for Others, 2021 - 2033 (USD Billion)

Chapter 8. Regional Business Analysis

8.1. Vaccine Market Share By Region, 2024 & 2033
8.2. North America
- 8.2.1. North America Vaccines Market 2021 - 2033 (USD Billion)
- 8.2.2. U.S.
  - 8.2.2.1. Key Country Dynamics
  - 8.2.2.2. Target Disease Prevalence
  - 8.2.2.3. Competitive Scenario
  - 8.2.2.4. Regulatory Framework
  - 8.2.2.5. Reimbursement Scenario
  - 8.2.2.6. U.S. Vaccine Market 2021 - 2033 (USD Billion)
- 8.2.3. Canada
  - 8.2.3.1. Key Country Dynamics
  - 8.2.3.2. Target Disease Prevalence
  - 8.2.3.3. Competitive Scenario
  - 8.2.3.4. Regulatory Framework
  - 8.2.3.5. Reimbursement Scenario
  - 8.2.3.6. Canada Vaccine Market 2021 - 2033 (USD Billion)
- 8.2.4. Mexico
  - 8.2.4.1. Key Country Dynamics
  - 8.2.4.2. Target Disease Prevalence
  - 8.2.4.3. Competitive Scenario
  - 8.2.4.4. Regulatory Framework
  - 8.2.4.5. Reimbursement Scenario
  - 8.2.4.6. Mexico Vaccine Market 2021 - 2033 (USD Billion)
8.3. Europe
- 8.3.1. Europe Vaccines Market 2021 - 2033 (USD Billion)
- 8.3.2. Germany
  - 8.3.2.1. Key Country Dynamics
  - 8.3.2.2. Target Disease Prevalence
  - 8.3.2.3. Competitive Scenario
  - 8.3.2.4. Regulatory Framework
  - 8.3.2.5. Reimbursement Scenario
  - 8.3.2.6. Germany Vaccine Market 2021 - 2033 (USD Billion)
- 8.3.3. UK
  - 8.3.3.1. Key Country Dynamics
  - 8.3.3.2. Target Disease Prevalence
  - 8.3.3.3. Competitive Scenario
  - 8.3.3.4. Regulatory Framework
  - 8.3.3.5. Reimbursement Scenario
  - 8.3.3.6. UK Vaccine Market 2021 - 2033 (USD Billion)
- 8.3.4. France
  - 8.3.4.1. Key Country Dynamics
  - 8.3.4.2. Target Disease Prevalence
  - 8.3.4.3. Competitive Scenario
  - 8.3.4.4. Regulatory Framework
  - 8.3.4.5. Reimbursement Scenario
  - 8.3.4.6. France Vaccine Market 2021 - 2033 (USD Billion)
- 8.3.5. Italy
  - 8.3.5.1. Key Country Dynamics
  - 8.3.5.2. Target Disease Prevalence
  - 8.3.5.3. Competitive Scenario
  - 8.3.5.4. Regulatory Framework
  - 8.3.5.5. Reimbursement Scenario
  - 8.3.5.6. Italy Vaccine Market 2021 - 2033 (USD Billion)
- 8.3.6. Spain
  - 8.3.6.1. Key Country Dynamics
  - 8.3.6.2. Target Disease Prevalence
  - 8.3.6.3. Competitive Scenario
  - 8.3.6.4. Regulatory Framework
  - 8.3.6.5. Reimbursement Scenario
  - 8.3.6.6. Spain Vaccine Market 2021 - 2033 (USD Billion)
- 8.3.7. Denmark
  - 8.3.7.1. Key Country Dynamics
  - 8.3.7.2. Target Disease Prevalence
  - 8.3.7.3. Competitive Scenario
  - 8.3.7.4. Regulatory Framework
  - 8.3.7.5. Reimbursement Scenario
  - 8.3.7.6. Denmark Vaccine Market 2021 - 2033 (USD Billion)
- 8.3.8. Sweden
  - 8.3.8.1. Key Country Dynamics
  - 8.3.8.2. Target Disease Prevalence
  - 8.3.8.3. Competitive Scenario
  - 8.3.8.4. Regulatory Framework
  - 8.3.8.5. Reimbursement Scenario
  - 8.3.8.6. Sweden Vaccine Market 2021 - 2033 (USD Billion)
- 8.3.9. Norway
  - 8.3.9.1. Key Country Dynamics
  - 8.3.9.2. Target Disease Prevalence
  - 8.3.9.3. Competitive Scenario
  - 8.3.9.4. Regulatory Framework
  - 8.3.9.5. Reimbursement Scenario
  - 8.3.9.6. Norway Vaccine Market 2021 - 2033 (USD Billion)
8.4. Asia Pacific
- 8.4.1. Asia Pacific Vaccine Market, 2021 - 2033 (USD Billion)
- 8.4.2. Japan
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. Target Disease Prevalence
  - 8.4.2.3. Competitive Scenario
  - 8.4.2.4. Regulatory Framework
  - 8.4.2.5. Reimbursement Scenario
  - 8.4.2.6. Japan Vaccine Market 2021 - 2033 (USD Billion)
- 8.4.3. China
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Target Disease Prevalence
  - 8.4.3.3. Competitive Scenario
  - 8.4.3.4. Regulatory Framework
  - 8.4.3.5. Reimbursement Scenario
  - 8.4.3.6. China Vaccine Market 2021 - 2033 (USD Billion)
- 8.4.4. India
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Target Disease Prevalence
  - 8.4.4.3. Competitive Scenario
  - 8.4.4.4. Regulatory Framework
  - 8.4.4.5. Reimbursement Scenario
  - 8.4.4.6. India Vaccine Market 2021 - 2033 (USD Billion)
- 8.4.5. South Korea
  - 8.4.5.1. Key Country Dynamics
  - 8.4.5.2. Target Disease Prevalence
  - 8.4.5.3. Competitive Scenario
  - 8.4.5.4. Regulatory Framework
  - 8.4.5.5. Reimbursement Scenario
  - 8.4.5.6. South Korea Vaccine Market 2021 - 2033 (USD Billion)
- 8.4.6. Australia
  - 8.4.6.1. Key Country Dynamics
  - 8.4.6.2. Target Disease Prevalence
  - 8.4.6.3. Competitive Scenario
  - 8.4.6.4. Regulatory Framework
  - 8.4.6.5. Reimbursement Scenario
  - 8.4.6.6. Australia Vaccine Market 2021 - 2033 (USD Billion)
- 8.4.7. Thailand
  - 8.4.7.1. Key Country Dynamics
  - 8.4.7.2. Target Disease Prevalence
  - 8.4.7.3. Competitive Scenario
  - 8.4.7.4. Regulatory Framework
  - 8.4.7.5. Reimbursement Scenario
  - 8.4.7.6. Thailand Vaccine Market 2021 - 2033 (USD Billion)
8.5. Latin America
- 8.5.1. Latin America Vaccine Market, 2021 - 2033 (USD Billion)
- 8.5.2. Brazil
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. Target Disease Prevalence
  - 8.5.2.3. Competitive Scenario
  - 8.5.2.4. Regulatory Framework
  - 8.5.2.5. Reimbursement Scenario
  - 8.5.2.6. Brazil Vaccine Market 2021 - 2033 (USD Billion)
- 8.5.3. Argentina
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Target Disease Prevalence
  - 8.5.3.3. Competitive Scenario
  - 8.5.3.4. Regulatory Framework
  - 8.5.3.5. Reimbursement Scenario
  - 8.5.3.6. Argentina Vaccine Market 2021 - 2033 (USD Billion)
8.6. MEA
- 8.6.1. MEA Vaccine Market, 2021 - 2033 (USD Billion)
- 8.6.2. South Africa
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. Target Disease Prevalence
  - 8.6.2.3. Competitive Scenario
  - 8.6.2.4. Regulatory Framework
  - 8.6.2.5. Reimbursement Scenario
  - 8.6.2.6. South Africa Vaccine Market 2021 - 2033 (USD Billion)
- 8.6.3. Saudi Arabia
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. Target Disease Prevalence
  - 8.6.3.3. Competitive Scenario
  - 8.6.3.4. Regulatory Framework
  - 8.6.3.5. Reimbursement Scenario
  - 8.6.3.6. Saudi Arabia Vaccine Market 2021 - 2033 (USD Billion)
- 8.6.4. UAE
  - 8.6.4.1. Key Country Dynamics
  - 8.6.4.2. Target Disease Prevalence
  - 8.6.4.3. Competitive Scenario
  - 8.6.4.4. Regulatory Framework
  - 8.6.4.5. Reimbursement Scenario
  - 8.6.4.6. UAE Vaccine Market 2021 - 2033 (USD Billion)
- 8.6.5. Kuwait
  - 8.6.5.1. Key Country Dynamics
  - 8.6.5.2. Target Disease Prevalence
  - 8.6.5.3. Competitive Scenario
  - 8.6.5.4. Regulatory Framework
  - 8.6.5.5. Reimbursement Scenario
  - 8.6.5.6. Kuwait Vaccine Market 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

9.1. Participant's overview
9.2. Financial performance
9.3. Participant categorization
- 9.3.1. Market Leaders
- 9.3.2. Vaccine Market Share Analysis, 2023
- 9.3.3. Company Profiles
  - 9.3.3.1. Serum Institute of India Pvt. Ltd.
    - 9.3.3.1.1. Company Overview
    - 9.3.3.1.2. Financial Performance
    - 9.3.3.1.3. Product Benchmarking
    - 9.3.3.1.4. Strategic Initiatives
  - 9.3.3.2. Seqirus
    - 9.3.3.2.1. Company Overview
    - 9.3.3.2.2. Financial Performance
    - 9.3.3.2.3. Product Benchmarking
    - 9.3.3.2.4. Strategic Initiatives
  - 9.3.3.3. Sanofi
    - 9.3.3.3.1. Company Overview
    - 9.3.3.3.2. Financial Performance
    - 9.3.3.3.3. Product Benchmarking
    - 9.3.3.3.4. Strategic Initiatives
  - 9.3.3.4. GSK Plc.
    - 9.3.3.4.1. Company Overview
    - 9.3.3.4.2. Financial Performance
    - 9.3.3.4.3. Product Benchmarking
    - 9.3.3.4.4. Strategic Initiatives
  - 9.3.3.5. Merck & Co., Inc.
    - 9.3.3.5.1. Company Overview
    - 9.3.3.5.2. Financial Performance
    - 9.3.3.5.3. Product Benchmarking
    - 9.3.3.5.4. Strategic Initiatives
  - 9.3.3.6. Pfizer Inc.
    - 9.3.3.6.1. Company Overview
    - 9.3.3.6.2. Financial Performance
    - 9.3.3.6.3. Product Benchmarking
    - 9.3.3.6.4. Strategic Initiatives
  - 9.3.3.7. Moderna Inc.
    - 9.3.3.7.1. Company Overview
    - 9.3.3.7.2. Financial Performance
    - 9.3.3.7.3. Product Benchmarking
    - 9.3.3.7.4. Strategic Initiatives
  - 9.3.3.8. Sinovac
    - 9.3.3.8.1. Company Overview
    - 9.3.3.8.2. Financial Performance
    - 9.3.3.8.3. Product Benchmarking
    - 9.3.3.8.4. Strategic Initiatives
  - 9.3.3.9. BioNTech SE
    - 9.3.3.9.1. Company Overview
    - 9.3.3.9.2. Financial Performance
    - 9.3.3.9.3. Product Benchmarking
    - 9.3.3.9.4. Strategic Initiatives
  - 9.3.3.10. AstraZeneca
    - 9.3.3.10.1. Company Overview
    - 9.3.3.10.2. Financial Performance
    - 9.3.3.10.3. Product Benchmarking
    - 9.3.3.10.4. Strategic Initiatives
- 9.3.4. Strategy Mapping
  - 9.3.4.1. Expansion
  - 9.3.4.2. Acquisition
  - 9.3.4.3. Collaborations
  - 9.3.4.4. Product/Service Launch
  - 9.3.4.5. Partnerships
  - 9.3.4.6. Others

ワクチンの市場規模、シェア、動向分析レポート：タイプ別、投与経路別、適応疾患別、年齢層別、流通チャネル別、地域別、セグメント予測、2025年～2033年

Vaccine Market Size, Share & Trends Analysis Report By Type (Subunit, mRNA), By Route Of Administration (Oral), By Disease Indication (HPV, MMR), By Age Group (Adult), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

ワクチン市場の成長と動向：

ワクチン市場のハイライト

目次

第1章調査手法と範囲

第2章市場の変数、動向、範囲

第3章タイプのビジネス分析

第4章投与経路のビジネス分析

第5章適応疾患のビジネス分析

第6章年齢層のビジネス分析

第7章流通チャネルのビジネス分析

第8章地域のビジネス分析

第9章競合情勢

List of Tables

List of Figures

Vaccine Market Growth & Trends:

Vaccine Market Report Highlights:

Table of Contents

Chapter 1. Methodology And Scope

Chapter 2. Market Variables, Trends, & Scope

Chapter 3. Type Business Analysis

Chapter 4. Route Of Administration Business Analysis

Chapter 5. Disease Indication Business Analysis

Chapter 6. Age Group Business Analysis

Chapter 7. Distribution Channel Business Analysis

Chapter 8. Regional Business Analysis

Chapter 9. Competitive Landscape

ワクチンの市場規模、シェア、動向分析レポート：タイプ別、投与経路別、適応疾患別、年齢層別、流通チャネル別、地域別、セグメント予測、2025年～2033年

Vaccine Market Size, Share & Trends Analysis Report By Type (Subunit, mRNA), By Route Of Administration (Oral), By Disease Indication (HPV, MMR), By Age Group (Adult), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

ワクチン市場の成長と動向：

ワクチン市場のハイライト

目次

第1章 調査手法と範囲

第2章 市場の変数、動向、範囲

第3章 タイプのビジネス分析

第4章 投与経路のビジネス分析

第5章 適応疾患のビジネス分析

第6章 年齢層のビジネス分析

第7章 流通チャネルのビジネス分析

第8章 地域のビジネス分析

第9章 競合情勢

List of Tables

List of Figures

Vaccine Market Growth & Trends:

Vaccine Market Report Highlights:

Table of Contents

Chapter 1. Methodology And Scope

Chapter 2. Market Variables, Trends, & Scope

Chapter 3. Type Business Analysis

Chapter 4. Route Of Administration Business Analysis

Chapter 5. Disease Indication Business Analysis

Chapter 6. Age Group Business Analysis

Chapter 7. Distribution Channel Business Analysis

Chapter 8. Regional Business Analysis

Chapter 9. Competitive Landscape

第1章調査手法と範囲

第2章市場の変数、動向、範囲

第3章タイプのビジネス分析

第4章投与経路のビジネス分析

第5章適応疾患のビジネス分析

第6章年齢層のビジネス分析

第7章流通チャネルのビジネス分析

第8章地域のビジネス分析

第9章競合情勢